ENLIVEN THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Capital Expenditures Incurred but Not yet Paid of $28.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-05
- 2026-06-30: Capital Expenditures Incurred but Not yet Paid 6 month $28.00K.
- 2025-06-30: Capital Expenditures Incurred but Not yet Paid 6 month $0.00.
- 2024-06-30: Capital Expenditures Incurred but Not yet Paid 6 month $23.00K.
- 2023-06-30: Capital Expenditures Incurred but Not yet Paid 6 month $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 6 month |
|---|---|
| 2026-06-30 | $28.00K 10-Q · filed 2026-08-05 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 |
| 2024-06-30 | $23.00K 10-Q · filed 2025-08-13 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |